Cargando…
1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy
BACKGROUND: Prophylactic antibiotics for the prevention of bloodstream infections (BSIs) during neutropenia (NTP) may reduce the incidence of BSIs, NTP fever, and mortality. However, antibiotics may also result in dysbiosis of the gut microbiome. We aimed to study the impact of levofloxacin prophyla...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254734/ http://dx.doi.org/10.1093/ofid/ofy210.1423 |
_version_ | 1783373792420036608 |
---|---|
author | Ziegler, Matthew Han, Jennifer H Landsburg, Daniel Pegues, David Reesey, Emily Gilmar, Cheryl Gorman, Theresa Bink, Kristen Moore, Amy Kelly, Brendan J |
author_facet | Ziegler, Matthew Han, Jennifer H Landsburg, Daniel Pegues, David Reesey, Emily Gilmar, Cheryl Gorman, Theresa Bink, Kristen Moore, Amy Kelly, Brendan J |
author_sort | Ziegler, Matthew |
collection | PubMed |
description | BACKGROUND: Prophylactic antibiotics for the prevention of bloodstream infections (BSIs) during neutropenia (NTP) may reduce the incidence of BSIs, NTP fever, and mortality. However, antibiotics may also result in dysbiosis of the gut microbiome. We aimed to study the impact of levofloxacin prophylaxis compared with broad-spectrum β-lactam (BSBL) antibiotics used for the treatment of NTP fever on gut microbiome features in patients with hematologic malignancy. METHODS: Stool specimens from hematologic malignancy patients admitted for chemotherapy or stem cell transplant (SCT) in the setting of the evaluation of diarrhea were collected from September 2017 to November 2017. Levofloxacin prophylaxis was standard of care for patients undergoing autologous SCT or induction chemotherapy for acute myeloid leukemia (AML). 16S rRNA (V1–V2 amplicon) sequencing was performed using the Illumina HiSeq platform, formation of operational taxonomic units (OTUs) was performed using QIIME 1.9.1, and taxonomic assignment was performed via the GreenGenes database (13.8). Descriptive statistics were used to compare microbiome features. RESULTS: A total of 57 samples from 44 patients were included, most with AML (42%), multiple myeloma (33%), or non-Hodgkin’s lymphoma (12%). In the 7 days prior to sample collection, 28 (49%) patients received a BSBL and 17 (29%) received levofloxacin. The gut microbiome of patients with BSBL exposure had significantly reduced Shannon alpha diversity compared with those without: median 1.96 (IQR 1.08–2.57) vs. 2.58 (IQR 2.05–2.93); P < 0.01. However, those with and without levofloxacin exposure showed no difference: median 2.37 (IQR 2.19–2.75) vs. 2.22 (IQR 1.71–2.81), respectively; P = 0.48. Additionally, those with BSBL exposure trended toward increased dominance with non-Bacteroidetes taxa: 14 (60%) vs. 14 (41%); P = 0.14. In contrast, levofloxacin exposure was associated with a lower risk of dominance: 2 (8%) vs. 15 (55%); P < 0.01 and was associated with a greater proportion of Bacteroidetes taxa: 75% vs. 27% (P < 0.01). CONCLUSION: Our findings suggest that the impact of antibiotics on the gut microbiome vary by class, and that levofloxacin may have limited impact on the gut microbiome in this patient population. Further studies are needed to investigate this potential differential impact of antibiotic classes. DISCLOSURES: D. Pegues, DaVita / Total Renal Care: Consultant, Consulting fee. |
format | Online Article Text |
id | pubmed-6254734 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62547342018-11-28 1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy Ziegler, Matthew Han, Jennifer H Landsburg, Daniel Pegues, David Reesey, Emily Gilmar, Cheryl Gorman, Theresa Bink, Kristen Moore, Amy Kelly, Brendan J Open Forum Infect Dis Abstracts BACKGROUND: Prophylactic antibiotics for the prevention of bloodstream infections (BSIs) during neutropenia (NTP) may reduce the incidence of BSIs, NTP fever, and mortality. However, antibiotics may also result in dysbiosis of the gut microbiome. We aimed to study the impact of levofloxacin prophylaxis compared with broad-spectrum β-lactam (BSBL) antibiotics used for the treatment of NTP fever on gut microbiome features in patients with hematologic malignancy. METHODS: Stool specimens from hematologic malignancy patients admitted for chemotherapy or stem cell transplant (SCT) in the setting of the evaluation of diarrhea were collected from September 2017 to November 2017. Levofloxacin prophylaxis was standard of care for patients undergoing autologous SCT or induction chemotherapy for acute myeloid leukemia (AML). 16S rRNA (V1–V2 amplicon) sequencing was performed using the Illumina HiSeq platform, formation of operational taxonomic units (OTUs) was performed using QIIME 1.9.1, and taxonomic assignment was performed via the GreenGenes database (13.8). Descriptive statistics were used to compare microbiome features. RESULTS: A total of 57 samples from 44 patients were included, most with AML (42%), multiple myeloma (33%), or non-Hodgkin’s lymphoma (12%). In the 7 days prior to sample collection, 28 (49%) patients received a BSBL and 17 (29%) received levofloxacin. The gut microbiome of patients with BSBL exposure had significantly reduced Shannon alpha diversity compared with those without: median 1.96 (IQR 1.08–2.57) vs. 2.58 (IQR 2.05–2.93); P < 0.01. However, those with and without levofloxacin exposure showed no difference: median 2.37 (IQR 2.19–2.75) vs. 2.22 (IQR 1.71–2.81), respectively; P = 0.48. Additionally, those with BSBL exposure trended toward increased dominance with non-Bacteroidetes taxa: 14 (60%) vs. 14 (41%); P = 0.14. In contrast, levofloxacin exposure was associated with a lower risk of dominance: 2 (8%) vs. 15 (55%); P < 0.01 and was associated with a greater proportion of Bacteroidetes taxa: 75% vs. 27% (P < 0.01). CONCLUSION: Our findings suggest that the impact of antibiotics on the gut microbiome vary by class, and that levofloxacin may have limited impact on the gut microbiome in this patient population. Further studies are needed to investigate this potential differential impact of antibiotic classes. DISCLOSURES: D. Pegues, DaVita / Total Renal Care: Consultant, Consulting fee. Oxford University Press 2018-11-26 /pmc/articles/PMC6254734/ http://dx.doi.org/10.1093/ofid/ofy210.1423 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Ziegler, Matthew Han, Jennifer H Landsburg, Daniel Pegues, David Reesey, Emily Gilmar, Cheryl Gorman, Theresa Bink, Kristen Moore, Amy Kelly, Brendan J 1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy |
title | 1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy |
title_full | 1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy |
title_fullStr | 1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy |
title_full_unstemmed | 1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy |
title_short | 1595. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients with Hematologic Malignancy |
title_sort | 1595. impact of levofloxacin for the prophylaxis of bloodstream infection on the gut microbiome in patients with hematologic malignancy |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254734/ http://dx.doi.org/10.1093/ofid/ofy210.1423 |
work_keys_str_mv | AT zieglermatthew 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT hanjenniferh 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT landsburgdaniel 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT peguesdavid 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT reeseyemily 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT gilmarcheryl 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT gormantheresa 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT binkkristen 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT mooreamy 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT kellybrendanj 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy AT 1595impactoflevofloxacinfortheprophylaxisofbloodstreaminfectiononthegutmicrobiomeinpatientswithhematologicmalignancy |